Muenchensteinerstrasse 38





Tel. +41 61 316 8111

Fax. +41 61 316 9111


Nutraceutical and Functional Food Ingredients, Vitamins

facebook Twitter Linkedin YouTube


Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment. 

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. 

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources. 

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Articles On NutritionInsight


Nutrition & Health News   10 December 2018

Lonza to establish strategic biomanufacturing base in China

10 Dec 2018 --- GE Healthcare is to develop a biologics facility for Lonza in Guangzhou, China, as part of a recently inked agreement. The facility is part of a larger biomanufacturing initiative between GE Healthcare and Guangzhou Development District (GDD). For the project to progress, Lonza will sign a memorandum of understanding with GDD. The new facility will give Lonza Pharma & Biotech a strategic base in China to respond to growing demand for high-quality CDMO services in the country.

Nutrition & Health News   01 November 2018

Lonza divests water business in US$630m deal to focus on growth of healthcare business

01 Nov 2018 --- Lonza has sold its Water Care business to Platinum Equity in a US$630 million deal. The move allows Lonza to focus on its healthcare continuum strategy, which includes patient healthcare, consumer preventive healthcare and consumer's healthy environment. The company posted strong Q3 results last week across the Healthcare Continuum. In the first half of this year, Lonza reported strong momentum with organic growth of 8 percent (like-for-like) sales and 11 percent CORE EBITDA. The company’s businesses along the healthcare continuum achieved double-digit organic sales growth.  

Nutrition & Health News   25 October 2018

Lonza reports strong momentum for Q3 boosted by businesses along the healthcare continuum

25 Oct 2018 --- Lonza has reported ongoing momentum in the third quarter (Q3), boosted by its businesses along the healthcare continuum, including Pharma & Biotech and Speciality Ingredients. The company reports it is capitalizing on organic growth opportunities such as its Ibex solutions, which it recently expanded.

More Articles

Nutrition Focus


02 October 2018

Bone and joint health: Increased focus on mobility and healthy aging

Products featuring bone & joint health claims are on the rise, with Innova Market Insights data showing a compound annual growth rate of 13 percent between 2013 and 2017.

industry focus image

Video Interviews


11 February 2019

Addressing clean label supplement demands

11 Feb 2019 --- Lonza recently revealed the global launch of its latest dosage form innovation: Capsugel Vcaps Plus plant-based capsules. The first of the next-generation clean label solutions to be marketed worldwide is the Vcaps Plus Purple Carrot capsule, following the successful introduction of the Vcaps Plus Blue Spirulina capsule in Europe earlier this year. The high-performance capsule shell is made using plant-based hypromellose (HPMC) and water only, without any preservatives. A colorant derived from purple carrots is used to match the desired shade as closely as possible, while maintaining a natural appearance in the finished supplement. Achieving unique visual appeal, the purple carrot color also provides masking capabilities.

17 January 2019

Innovating in ready-to-market formulations

17 Jan 2019 --- Stephane Vouche, of Lonza Capsugel, spoke to NutritionInsight at Health Ingredients Europe (HiE) in 2018 on innovating in ready-to-market formulations. Vouche shared that Lonza was presenting new formulations at the show. One particular innovation included a combination capsule with Lonza's UCT-II ingredient for joint health with curcumin. This combination creates a powerful one-pill solution, meaning consumers do not need to take multiple pills, Vouche said.

22 May 2018

Integrating Capsugel innovation

22 May 2018 --- Lonza Consumer Health & Nutrition brought innovation through form and function for its latest ingredients, delivery systems and finished product formulations for the nutraceuticals industry to Vitafoods Europe 2018. Visitors could see how innovative ingredients can be combined with cutting-edge dosage forms from the legacy Capsugel business, including DUOCAP capsule-in-capsules and Lipid Multi Particulate (LMP) technology, to create market-ready products positioned on a healthy aging, probiotics or active & sports nutrition platform, among others. In addition, the company highlighted its blue algae Vcaps Plus Spirulina capsule, the next generation of vegetarian food colored capsules, designed to support the development of true clean label solutions.

More Videos



19 October 2018

Driving growth in the joint health category: UC-II® undenatured type II collagen

19 Oct 2018 --- UC-II® undenatured type II collagen is a once-a-day joint health solution for the joint health market. Its small dose size and mode of action help make it the preferred choice among top food supplement manufacturers and retailers. Learn why UC-II® undenatured type II collagen is a success story and discover new ready-to-market solutions.

06 February 2018

L-Carnitine – discover new market opportunities

06 Feb 2018 --- First utilized as an essential ingredient in infant nutrition, the market potential of L-Carnitine has evolved in recent years to now provide beneficial support across multiple product categories. L-Carnitine is enjoying significant growth of almost 31 percent in food and beverages with sports-related claims when comparing 2012 and 2017 launch activity. Further innovation is taking place as the mainstreaming of sports nutrition accelerates.